Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025

中国の製薬市場:動向、改革、機会、収益予測

◆タイトル:Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025
◆商品コード:VGAIN5091106
◆調査・発行会社:visiongain
◆発行日:2015年8月
◆ページ数:253
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、中国の製薬市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・中国の製薬市場:ディスカッション及び市場予想
・医療の需要
・中国の製薬市場:主要治療分野別分析/市場規模
・中国の製薬市場:製品クラス別分析/市場規模
・中国の製薬市場:薬品種類別分析/市場規模
・中国の製薬市場:販売チャネル/市場規模
・主要企業分析
・専門家の見解

Pharma Sales in China – How to Assess Trends and Potential Revenues, Benefiting Your Influence
What does the future hold for China’s pharma market? Can it sustain high growth? Visiongain’s new report gives you forecasted revenues there to 2025. Our work explains medical and technological trends, prospects and commercial opportunities.

China retains great potential for sales of prescription drugs and OTC medicines. Our updated study gives data and multilevel revenue predictions. There you investigate activities of domestic and international companies, assessing prospects for their expanding market.

Our analysis shows you the most lucrative parts of Chinese pharmaceutical sales. Read on, then, to explore that market and see what revenue it could achieve in future.

Forecasts and other analyses to help you stay ahead on China’s pharma market
Our new survey shows you revenue predictions to 2025, historical data, growth rates and market shares. It explores business outlooks, trends and leading companies. With that work you gain 76 tables, 82 charts and two interviews with organisations.

Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses, plans, decisions and authority. The following sections explain how our investigation helps your work.

Sales predictions for the Chinese drug market and its segments – discover sales potentials
Along with revenue prediction for the overall Chinese pharma market, our study shows individual forecasting to 2025 for these therapeutic submarkets:
• Infectious diseases – antibiotics and other anti-infective products
• Cancer – applications in oncology, anticancer agents
• Cardiovascular disorders – with sub-forecasts for hypertension and dyslipidaemia
• Diabetes therapies
• Respiratory diseases – with sub-forecasts for COPD and asthma treatments
• Autoimmune conditions
• Central nervous system (CNS) disorders – with sub-forecasting for antidepressants
• Other medical needs (grouped).

Our report also gives individual revenue forecasts to 2025 by product class and sales channel:
• Small-molecule pharmaceuticals – with sub forecasts for original-branded medicines prescription drugs and generics
• Biological drugs – with sub forecasts for novel biologics, biosimilars and vaccines
• Traditional Chinese medicines (TCM)
• Hospitals
• Retail pharmacies
• Clinics and other channels
• Over-the-counter (OTC) products.

China remains an exciting and important market for pharmaceutical companies. Our study shows you what is possible there from 2015, including high demand for treatments.

For prominent diseases in China, our survey lets you assess prevalence and incidence rates to 2025. Discover treatment opportunities for pharmaceutical companies from 2015.

With our analysis you explore what influences Chinese healthcare industries and markets.

Trends, characteristics and other forces shaping the Chinese pharma market
Our report discusses issues, regulations and other events influencing Chinese healthcare and related industries from 2015:
• Epidemiological trends – explore treatment needs underpinning Chinese healthcare
• Institutions regulating the pharmaceutical industry – policy generation
• Chinese healthcare reform – initiatives, e.g. Healthy China 2020, affecting drug producers and marketers
• Opportunities in treating chronic diseases, including HIV and hepatitis
• Protection of intellectual property – progress and challenges
• Sales outlets – distribution channels most important from 2015 to 2025.

Our study also discusses other aspects of medical businesses in China, including these developments:
• Manufacturing and R&D, including biotechnology and trends for venture capital
• Healthcare funding – driving and restraining forces
• Discussion of the Anhui model and its implications
• Investment in rural healthcare – high demands needing served, giving opportunities
• Branded generics – their prospects for expanding treatment coverage
• Biosimilar drug manufacturers – harnessing China’s strengths in biopharma.

With our investigation you explore technological, economic, social and political trends. You also analyse that market’s strengths, weaknesses, opportunities and threats. Discover, from 2015 to 2025, what the future holds for pharma companies operating in China.

Leading companies – domestic and foreign – and overall 2019 market value
What happens next? Our report predicts overall pharma sales in China will reach $227bn in 2019, expanding onwards to 2025. Explore what is possible in that vast, fast-growing market.

Our study covers these multinational companies and other foreign organisations developing that market:
• AbbVie
• Eli Lilly
• GlaxoSmithKline
• AstraZeneca
• Johnson & Johnson
• Novo Nordisk
• Novartis
• Bayer
• Pfizer
• Roche
• Merck & Co.

Our survey also discusses leading Chinese pharma companies, with ranking of the top 50 by revenue. See the roles they serve and their outlooks for the future. These and many other domestic firms appear in the study:
• Guangzhou Pharmaceutical Holdings
• Shanghai Pharmaceuticals
• Yunnan Baiyao
• Harbin Pharmaceuticals
• Xiuzheng Pharmaceutical Group
• Sinopharm.

【レポートの目次】

1. Report Overview
1.1 The Chinese Pharmaceutical Market, 2015-2025
1.2 Chinese Pharmaceutical Market: Segmentation, 2015
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Chinese Healthcare: Overview, 2015
2.1 China: Demographic Indicators Overview, 2015
2.2 Chinese Healthcare System: Overview, 2015
2.3 Analysis of China’s Healthcare Expenditure
2.4 The Chinese System: Who Really Pays the Bill?
2.5 State Bodies Regulating the Chinese Pharmaceutical Market
2.6 Healthy China 2020: The Government’s Long-term Plan
2.7 Analysis of the Potential of ‘Healthy China Initiative’, 2015
2.8 The Big Debate About Healthcare Funding

3. Chinese Pharmaceutical Market: Discussions and Predictions, 2015-2025
3.1 Chinese Pharmaceutical Market: The Second Biggest Market in the World, 2014
3.2 Chinese Pharmaceutical Market: Overall Revenue Forecast, 2015-2025

4. Medical Treatment Needs in China, 2015-2025
4.1 Disease Prevalence in China, 2015-2025
4.2 Disease Incidence in China, 2015-2025
4.3 Disease Mortality Rates in China, 2015-2025
4.3.1 Top 5 Broad Causes of Death in China
4.3.2 Stoke and Cancers: China’s Top Killers
4.3.3 Top Causes of Death in China: Mortality Projections, 2015-2025

5. Chinese Pharmaceutical Market: Leading Therapeutic Areas, 2015-2025
5.1 Leading Therapeutic Areas in the Chinese Pharmaceutical Market: Overview, 2014
5.2 Chinese Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2015-2025
5.3 Chronic Diseases Overtook the Infectious Diseases Segment, 2015-2025
5.4 Expanding China’s EDL: Reimbursement Focus on Key Therapies
5.5 Cardiovascular Therapeutic Segment: Overview, 2015
5.5.1 Cardiovascular Drugs Market: Forecast, 2015-2025
5.5.2 Hypertension in China Reaches Unprecedented Levels
5.5.3 Chinese Hypertension Drugs Market Continuing to Thrive: Forecast, 2015-2025
5.5.4 Chinese Hypertension Drugs Market: Leading Products
5.5.5 Treatment of Chinese Hypertensive Patients
5.5.6 Dyslipidaemia: Overview of China’s Most Prevalent Disease
5.5.7 Treatment of Dyslipidaemia Affected by Reimbursement Issues
5.5.8 Chinese Dyslipidaemia Market Prospects: Forecast, 2015-2025
5.5.9 Chinese Cardiovascular Disease Segment: Major Focus of Western Companies
5.5.10 Big Pharma Companies Dominate the Chinese Hypertension Drugs Market
5.5.11 Increasing Domestic Company Presence in the Cardiovascular Therapeutic Segment
5.5.12 Drivers and Restraints for the Chinese Cardiovascular Drugs Market, 2015
5.6 Anticancer Therapeutic Segment: Overview, 2015
5.6.1 Anticancer Drugs will be the Largest Segment of the Chinese Pharmaceutical Market by 2025: Forecast, 2015-2025
5.6.2 Cancer Incidence Boosts the Eminence of China’s Anticancer Drugs Market, 2015-2025
5.6.3 Targeted Anticancer Therapeutics Making Progress in China
5.6.4 Chinese Pharma Companies Focusing on Anticancer Drugs
5.6.5 Eli Lilly and Innovent Biologics’ Strategic Alliance: New Big Player in China’s Anticancer Market?
5.6.6 Improved Healthcare Coverage for Cancer Patients Promises Strong Revenue Stream from Anticancer Drugs
5.6.7 Marketing Innovative Anticancer Drug in China – Example from Roche
5.6.8 Negative Impact of Late Cancer Diagnosis
5.6.9 Cost of Treatment Critical for the Choice of Anticancer Medicine
5.6.10 Tailored Anticancer Treatment for the Chinese Market – Notable Companies and their Developments
5.6.11 Biomarker Testing in China – What Improvement is Possible?
5.6.12 Drivers and Restraints for the Anticancer Drugs Segment, 2015
5.7 Infectious Disease Therapeutics: Overview, 2015
5.7.1 Infectious Disease Drugs Market: Forecast, 2015-2025
5.7.2 What Makes China Prominent for Antibiotics Use: Analysis of Cephalosporin, 2015
5.7.3 China’s Infectious Disease Market Dominated by Domestic Companies
5.7.4 Antibiotics Over-use Reported in China: Causes and Results
5.7.5 HIV and Hepatitis in China: Growing Therapeutic Areas Worth Watching
5.7.6 Hepatitis C Drug Challenges
5.7.7 Drivers and Restraints for the Infectious Diseases Pharma Segment, 2015
5.8 Diabetes Therapeutic Segment: Overview, 2015
5.8.1 Diabetes Drugs Market: Forecast, 2015-2025
5.8.2 Multinational Companies in the Chinese Diabetes Drug Market: Overview and Analysis, 2015
5.8.3 Domestic Companies Competing in the Chinese Diabetes Drug Market
5.8.4 Diabetes in China: Challenges and Opportunities
5.8.5 Drivers and Restraints for the Diabetes Drugs Segment, 2015
5.9 Respiratory Therapeutic Segment: Overview, 2015
5.9.1 Respiratory Disease Drugs Market: Forecast, 2015-2025
5.9.2 Chinese COPD Market: How Profitable Could it Be?
5.9.3 Chinese COPD Treatments Market: Predicted Revenue Increase – Forecast, 2015-2025
5.9.4 Chinese Asthma Drugs Market to Give Dependable Growth: Forecast, 2015-2025
5.9.5 Domestic Respiratory Drug Producers
5.9.6 Leading Respiratory Disease Drugs in China
5.9.7 AstraZeneca Sustains Market Penetration through Collaboration and Research
5.9.8 Drivers and Restraints for the Respiratory Diseases Segment, 2015
5.10 Central Nervous System (CNS) Therapeutics: Overview, 2015
5.10.1 CNS Drugs Market: Forecast, 2015-2025
5.10.2 By 2025 Over 7 Million People in China will Suffer from Depression:
5.10.3 Depression Drugs Market in China will Reach a 25% Annual Growth Rate: Forecast, 2015-2025
5.10.4 Domestic Companies in China’s CNS Disorders Market
5.10.5 China’s Aging Population: Driver for the CNS Segment
5.10.6 Rise of Dementia and Alzheimer’s Disease Presents Strong Market Opportunity
5.10.7 High Demand for Pain Relief Medicines in China
5.10.8 Drivers and Restraints for the CNS Drugs Segment, 2015
5.11 Immunomodulators: Overview, 2015
5.11.1 Autoimmune Drugs Market: Forecast, 2015-2025
5.11.2 Notable Chinese Companies in the Immunomodulators Market
5.11.3 Challenges Erode the Immunomodulator Market’s Potential
5.11.4 Immunomodulator Treatments to Gain Momentum in China
5.11.5 Drivers and Restraints for the Autoimmune Drugs Segment, 2015

6. Chinese Pharmaceutical Market: Leading Product Classes, 2015-2025
6.1 Product Classes in the Chinese Pharmaceutical Market: Overview, 2014
6.2 Chinese Pharmaceutical Market: Product Classes Forecasts, 2015-2025
6.3 Small Molecules: Overview, 2015
6.3.1 Chinese Small Molecule Drugs Market: Forecast, 2015-2025
6.3.2 Generics: Growth Engine for the Small Molecules Segment
6.3.3 Healthcare Reform Provides Opportunities for Original-Branded and Generic Drugs
6.3.4 Drivers and Restraints for the Small Molecule Treatments Market in China, 2015
6.4 Traditional Chinese Medicine (TCM): Overview, 2015
6.4.1 Traditional Chinese Medicine Market: Forecast, 2015-2025
6.4.2 Investments in TCM Development: Analysis of China’s TCM Market, 2015
6.4.3 Expansion of the TCM Market
6.4.4 Leading Chinese Companies in the TCM Segment, 2015
6.4.5 Drivers and Restraints for the Traditional Chinese Medicines Market, 2015
6.5 Chinese Biological Drugs Market: Overview, 2015
6.5.1 Chinese Biologics Market: Forecasts, 2015-2025
6.5.2 Branded Biologics Perform Well in China: Forecast, 2015-2025
6.5.3 Biomedicines Set for Strategic Growth: Analysis of China’s Fastest Growing Product Class, 2015
6.5.4 Roche Finding a Way Forward in China with Branded Biologics
6.5.5 Chinese Vaccines Market: Overview, 2015
6.5.6 China: the World’s Fifth Largest Vaccine Market
6.5.7 Chinese Vaccines Segment Loses Share: Forecast, 2015-2025
6.5.8 Companies Dominating the Vaccines Market in China
6.5.9 Domestic Manufacturer Supplies 80% of Vaccines in China
6.5.10 Multinational Companies Compete for a Share of the Chinese Vaccines Market
6.5.11 Hepatitis B Vaccine in China – a Story of Success
6.5.12 Chinese Biosimilars Market: Overview, 2015
6.5.13 Chinese Biosimilars Market: Forecast, 2015-2025
6.5.14 Biosimilars Account for Small Proportion of Biological Drug Revenues in China: When will this Change?
6.5.15 Chinese Biosimilar Development Guidelines Set for Release
6.5.16 Leading Chinese Biosimilar Manufacturers
6.5.17 Market Access for Biosimilars: Critical to Leverage Opportunities in China
6.5.18 Drivers and Restraints of the Chinese Biologics Market

7. Chinese Pharmaceutical Market: Leading Drug Types, 2015-2025
7.1 Drug Types in the Chinese Market: Overview, 2014
7.2 Growth Forecasts for Leading Drug Types in China, 2015-2025
7.3 Generic Drugs Dominate the Chinese Pharmaceutical Market
7.3 Generic Prescription Drugs Market in China: Forecast, 2015-2025
7.3.1 Chinese Pharmaceutical Market Structure Favours Generics’ Sales
7.3.2 Which Drugs Benefit More from the Government’s Healthcare Reform: Original-Patented or Generic?
7.3.3 Many Chinese Patients Favour Branded Generics
7.3.4 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Market
7.4 Chinese Over-the-Counter (OTC) Medicines Market: Forecast, 2015-2025
7.4.1 Chinese OTC Drugs Segment: Insights and Analysis of the Market’s Potential, 2015
7.4.2 China: The World’s Biggest OTC Pharmaceuticals Market
7.4.3 Leading Domestic Companies in the Chinese OTC Market, 2015
7.4.4 Bayer: The Biggest Multinational Player in China’s OTC Market
7.5 Chinese Patented Prescription Drugs Market: Forecast, 2015-2025
7.5.1 Chinese Patented Prescription Drugs Market: Factors Stimulating Sales Growth

8. Chinese Pharmaceutical Market: Sales Channels, 2015-2025
8.1 Chinese Pharmaceutical Market: Sales Channels Overview and Value, 2014
8.2 Chinese Pharmaceutical Market: Sales Channels Forecasts, 2015-2025
8.3 Only Five Domestic Companies Have a Sizable Share of the Chinese Pharma Distribution Market
8.4 Chinese Distribution Channels are Highly Fragmented Compared to Western Counterparts
8.5 Chinese Distribution Channels: Why Consolidation is Essential?
8.6 Shift Towards Consolidation within the Distribution Chain: Key Market Developments
8.7 China’s Drugs Distribution Environment: Issues and Challenges
8.8 Chinese Distribution Value Chain Follows a Complex Model
8.9 Chinese Pharmaceutical Distribution Network Comprises the World’s Largest Sales Force
8.10 Bribery Penalties: Indication of China’s Changing Pharmaceutical Distribution Practices
8.11 Hospital Sales Channels: Forecast, 2015-2025
8.11.1 Hospitals: Foundation of the Chinese Healthcare System
8.11.2 Chinese Public Hospitals: Healthcare Reform’s Priority
8.11.3 How does the Medicines Mark-up Ban Affect Hospitals’ Revenues?
8.12 Retail Pharmacies Channels: Forecast, 2015-2025
8.12.1 Difficulties in Retail Pharmacy Market Estimates
8.12.2 Online Pharmacies: the New Big Market Opportunity in China
8.13 Grassroot Clinics’ Sales Channels: Forecast, 2015-2025
8.13.1 Rural Investment will Facilitate Drug Sales Growth in Grassroot Clinics
8.14 Other Sales Channels: Forecast, 2015-2025
8.14.1 Other Sales Channels: The Grey Pharmaceuticals in China

9. Leading Companies in the Chinese Pharmaceuticals Market, 2015
9.1 Top 50 Domestic Chinese Pharmaceutical Companies, 2014
9.2 China’s Pharma is Highly Fragmented Compared to Other Prominent Markets
9.3 Leading Chinese Contract Research Organisations
9.4 Leading Multinational Companies in the Chinese Pharmaceutical Market: Strategies that Win, 2015
9.4.1 MNC Revenue and Market Share Estimates, 2014
9.4.2 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Segment
9.4.3 Bayer – Exceeding $3bn of Pharma Sales in China Possible?
9.4.4 Pfizer’s Strategic Approach in China – Does it Work?
9.4.5 Multinational Contract Research Organisations in China
9.5 New Policies Shift the Market Dynamics for Leading Players
9.6 Emerging Strategies to Boost Drug Sales and Comply with Regulations
9.7 What is Next in China for Multinational Pharma Companies?
9.8 Drivers and Restraints for Big Pharma’s Sales Growth in China, 2015

10. Research Interviews
10.1 Interview with Dr Greg Scott, Founder, ChinaBio Group
10.1.1 Future Prospects for the Chinese Pharmaceutical Market
10.1.2 Cancer is at the Forefront of Drug Development in China
10.1.3 Biologics in China – Biosimilars to Lead the Way
10.1.4 The Anhui Model – Discussion
10.1.5 IP Protection in China – Outlook
10.1.6 Consolidating the Fragmented Chinese Market
10.1.7 Access to the Chinese Pharmaceutical Market
10.2 Interview with Julie Li, Strategy Manager, China Resources Double-Crane Pharmaceuticals, China
10.2.1 Multinational Companies Dominate Drug Discovery in China
10.2.2 Cancer and Chronic Disease are Critical Areas in China
10.2.3 The Impact of Control on Antibacterial Drug Prescriptions
10.2.4 Potential for Consolidation of the Chinese Pharma Industry

11. Qualitative Analysis of the Chinese Pharmaceutical Market, 2015
11.1 Strengths: Increasing Investment in the Healthcare System
11.1.1 The Disease Burden Grows; So Does GDP
11.1.2 Chinese Pharmaceutical Market Still Has Untapped Potential
11.1.3 Progressive Urbanisation Continues to Drive Healthcare Spending
11.1.4 New Policies Recognise the Importance of IP
11.1.5 Research Hub for Asia Pacific and Beyond
11.2 Weaknesses: Imbalance of Resources and Quality Challenges
11.2.1 Healthcare Quality Issues Hit the Chinese Pharmaceutical Market
11.2.2 Highly Fragmented Pharmaceutical Market
11.2.3 Reimbursement and Market Access
11.2.4 Limited First-Class Laboratory Facilities Reported
11.2.5 Regulations and Clinical Trial Research
11.3 Opportunities: Quickly Emerging Volume Growth
11.3.1 Tailored Strategies to Meet the Chinese Pharma Market’s Need
11.3.2 Portfolio Diversification Matters
11.3.3 Enhancing Consolidation Activities
11.3.4 Innovative Biotechnology Sector
11.3.5 Liberal Regulations on Stem Cells Research
11.4 Threats: What if Things Go Wrong in China?
11.4.1 Strong Government Intervention
11.4.2 Anhui Model and its Results
11.5 Social Forces: The Increasing Power of China’s Demographics
11.5.1 The Ageing Dragon
11.5.2 The Obesity Epidemic
11.5.3 Social Changes and Their Effect on China’s Shifting Medical Treatment Patterns
11.6 Technological Factors: Embracing Technology and Increasing R&D Capabilities
11.6.1 National Database and Telemedicine: New Trends Shaping the Industry
11.6.2 Developing China’s R&D Capabilities through Technology
11.6.3 China Has the World’s Largest and Most Affordable Genomic Sequencing Facilities
11.7 Economic Factors: Economic Growth Closely Related to the Chinese Pharmaceutical Market Growth
11.7.1 China’s Rise as an Economic Superpower
11.7.2 Underlying Problems of China’s Economic Growth
11.7.3 How Many Five-Year Plans will Follow?
11.8 Political: The Chinese Government Possesses the Ultimate Power

12. Conclusions
12.1 China’s Healthcare Reform: Crucial Factor for Pharmaceutical Market Growth
12.2 China: the Country Driving Growth for the World’s Pharmaceutical Market, 2015-2025
12.3 Cancer Will Form a Main Therapeutic Segment in the Chinese Pharmaceutical Market
12.4 Generic and OTC Drugs Set to Remain the Main Product Types, but Patented Drugs will Experience Momentum
12.5 Pharmacy Sales are the Next Big Market Opportunity in China
12.6 Domestic Companies Still Dominate the Chinese Pharma Market, Amid Increasing Competition from MNCs
12.7 Concluding Thoughts on the Research and Analysis

List of Tables
Table 1.1 Chinese Pharmaceutical Market Forecast by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 2.1 China: Demographic Indicators, 2005-2014
Table 2.2 Healthcare Expenditure: Leading Markets and BRIC Countries, Total (%) of GDP, 2005-2013
Table 2.3 Chinese Institutions Regulating the Pharmaceutical and Healthcare Industries in China, 2015
Table 2.4 Chinese Healthcare Reform: Significant Initiatives, 2009-2015
Table 3.1 Regional Pharmaceutical Markets of the World: Market Size ($bn), Market Share (%), 2014
Table 3.2 Chinese Pharmaceutical Market Overall Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 4.1 Projections of Common Diseases’ Prevalence in China: Prevalence (000s) (%), CAGR (%), 2015-2025
Table 4.2 Projections of Common Diseases’ Incidence in China: Incidence (000s), CAGR (%), 2015-2025
Table 4.3 Top 5 Causes of Death per (000s) in China’s Urban and Rural Areas, 2013
Table 4.4 Top 15 Broad Causes of Death in China: Deaths (000s), Proportion of Overall Deaths (%), 2012
Table 4.5 Top 25 Causes of Death in China: Projected Deaths (000s), Share of Overall Deaths (%), CAGR (%) 2015-2025
Table 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Market Share (%), 2014
Table 5.2 Chinese Pharmaceutical Market by Therapy Area: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.3 Chinese Pharmaceutical Market by Therapy Area: Market Share Forecast (%), 2015-2025
Table 5.4 Selected High Profile New Entrants to China’s 2012 Essential Drugs List
Table 5.5 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.6 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 5.7 Chinese Hypertension Market by Drug Class: Market Size ($bn), Market Share (%), 2014
Table 5.8 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 5.9 Top Companies in the Chinese Hypertension Market: Revenue ($bn), Market Share (%), 2014
Table 5.10 Leading Domestic Chinese Cardiovascular Drug Manufacturers and Their Activities, 2015
Table 5.11 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.12 Projected Incidence of Types of Cancer in China: Incidence (000s), CAGR (%), 2015-2025
Table 5.13 Selected Domestic Chinese Anticancer Drug Manufacturers and Their Activities, 2014
Table 5.14 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.15 Chinese Infectious Disease Drugs Market by Drug Class: Market Size ($bn), Market Share (%), 2014
Table 5.16 Domestic Antibacterial Drug Manufacturers and Their Activities, 2015
Table 5.17 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.18 Selected Domestic Chinese Diabetes Drug Manufacturers and Their Activities, 2015
Table 5.19 Chinese Respiratory Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.20 Chinese COPD Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 5.21 Chinese Asthma Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025
Table 5.22 Selected Domestic Companies in the Respiratory Market and Their Activities, 2015
Table 5.23 Chinese Respiratory Drug Market by Product Class: Sales ($bn), Market Share (%), 2014
Table 5.24 Chinese CNS Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.25 Chinese Antidepressants Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Table 5.26 Selected Domestic Companies in the CNS Market and Their Activities, 2015
Table 5.27 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 5.28 Selected Chinese Immunomodulator Drug Companies and Their Activities, 2015
Table 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), 2014
Table 6.2 Chinese Pharmaceutical Market by Product Class: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.3 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.4 Chinese Small Molecule Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.5 Traditional Chinese Medicine Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.6 Selected TCM Manufacturers and their Activities, 2015
Table 6.7 Chinese Biological Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.8 Chinese Branded Biologics Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.9 Chinese Vaccines Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 6.10 Chinese Biosimilars Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), Market Share (%), 2014
Table 7.2 Chinese Pharmaceutical Market by Drug Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 7.3 Chinese Generic Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 7.4 Chinese Over-the-Counter Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 7.5 Selected Chinese OTC Drug Manufacturers and Their Activities, 2015
Table 7.6 Chinese Patented Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2014
Table 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), Market Share (%), 2014
Table 8.3 Chinese Pharmaceutical Market by Sales Channel: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 8.4 Chinese Hospital Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 8.5 Number of Healthcare Institutions in China, 2013
Table 8.6 Chinese Retail Pharmacy Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 8.7 Chinese Grassroot Clinics Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 8.8 Chinese Pharmaceutical Sales Through Other Channels: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025
Table 9.1 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (1-25), Revenue ($bn), Market Share (%), 2014
Table 9.2 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (26-50), Revenue ($bn), Market Share (%), 2014
Table 9.3 Selected Domestic Contract Research Organisations and Their Activities, 2015
Table 9.4 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (A), 2015
Table 9.5 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (B), 2015
Table 9.6 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (D-E), 2015
Table 9.7 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (G-J), 2015
Table 9.8 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (M-N), 2015
Table 9.9 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (O-T), 2015
Table 9.10 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue ($bn), Market Share (%), 2014
Table 12.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025
Table 12.2 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025
Table 12.3 Summary of Chinese Pharmaceutical Sales Channels: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025

List of Figures
Figure 1.1 Chinese Pharmaceutical Market Segmentation, 2015
Figure 2.1 China: Annual GDP Growth (%) and Healthcare Expenditure as Total (%) of GDP, 2005-2013
Figure 2.2 Leading Markets and BRIC Countries Healthcare Expenditure: Total (%) of GDP, 2005-2013
Figure 2.3 Out-of-pocket Health Expenditures: (%) of Private Spending on Healthcare, 2005-2013
Figure 3.1 Chinese Pharmaceutical Market: Value Chain, 2015
Figure 3.2 Regional Pharmaceutical Markets of the World: Market Share (%), 2014
Figure 3.3 Chinese Pharmaceutical Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 4.1 Top 5 Broad Causes of Death in China Urban Areas, 2013
Figure 4.2 Top 5 Broad Causes of Death in China Rural Areas, 2013
Figure 4.3 Top 10 Specific Causes of Death in China: Proportion of Overall Deaths (%), 2012
Figure 4.4 Leading Causes of Death in China: Projected Deaths (000s), 2015 and 2025
Figure 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), 2014
Figure 5.2 Chinese Pharmaceutical Market by Therapy Area: Revenue Forecasts ($bn), 2015-2025
Figure 5.3 Chinese Pharmaceutical Market by Therapy Area: Proportional Revenue Increase ($bn), 2015-2025
Figure 5.4 Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2014
Figure 5.5 Forecast Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2025
Figure 5.6 Chinese Cardiovascular Disease Market: Segmentation by Drug Class, 2015
Figure 5.7 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.8 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.9 Chinese Hypertension Market by Drug Class: Market Share (%), 2014
Figure 5.10 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.11 Top Companies in the Chinese Hypertension Market: Market Share (%), 2014
Figure 5.12 Chinese Cardiovascular Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.13 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.14 Incidence of Types of Cancer in China: Incidence (000s), 2015-2025
Figure 5.15 Chinese Anticancer Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.16 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.17 Chinese Antibacterial Drugs Market by Drug Class: Market Share (%), 2014
Figure 5.18 Chinese Infectious Disease Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.19 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.20 Chinese Diabetes Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.21 Chinese Respiratory Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.22 Chinese COPD Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.23 Chinese Asthma Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.24 Chinese Respiratory Disease Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.25 Chinese CNS Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.26 Chinese Antidepressants Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.27 Chinese CNS Drugs Market: Drivers and Restraints, 2015-2025
Figure 5.28 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 5.29 Chinese Autoimmune Drugs Market: Drivers and Restraints, 2015-2025
Figure 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2014
Figure 6.2 Chinese Pharmaceutical Market by Product Class: Revenue Forecasts ($bn), 2015-2025
Figure 6.3 Chinese Pharmaceutical Market by Product Class: Proportional Revenue Increases ($bn), 2015-2025
Figure 6.4 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 6.5 Chinese Small Molecule Drugs Market by Product Type: Generic and Branded Drugs Proportional Revenue Increases ($bn), 2015-2025
Figure 6.6 Chinese Small Molecule Drugs Market by Product Type: Generic and Branded Drugs Annual Growth Rate Forecasts (%), 2015-2025
Figure 6.7 Chinese Small Molecule Drugs Market: Drivers and Restraints, 2015-2025
Figure 6.8 Traditional Chinese Medicine Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 6.9 Traditional Chinese Medicine Market: Drivers and Restraints, 2015-2025
Figure 6.10 Chinese Biological Drugs Market by Product Type: Revenue Forecasts ($bn), 2015-2025
Figure 6.11 Chinese Biological Drugs Market by Product Type: Proportional Revenue Increases ($bn), 2015-2025
Figure 6.12 Chinese Branded Biologics Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 6.13 Chinese Vaccines Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 6.14 Chinese Biosimilars Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 6.15 Chinese Biosimilar Manufacturers and Their Product Lines, 2015
Figure 6.16 Chinese Biologics Market: Drivers and Restraints, 2015-2025
Figure 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), 2014
Figure 7.2 Chinese Pharmaceutical Market by Drug Type: Market Share (%), 2014
Figure 7.3 Chinese Pharmaceutical Market by Drug Type: Revenue Forecasts ($bn), 2015-2025
Figure 7.4 Chinese Pharmaceutical Market by Drug Type: Proportional Revenue Increase ($bn), 2015-2025
Figure 7.5 Chinese Generic Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%),2015-2025
Figure 7.6 Chinese Over-the-Counter Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 7.7 Chinese Patented Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2014
Figure 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), 2014
Figure 8.3 Chinese Pharmaceutical Market by Sales Channel: Market Share (%), 2014
Figure 8.4 Chinese Pharmaceutical Market by Sales Channels: Revenue Forecasts ($bn), 2015-2025
Figure 8.5 Chinese Pharmaceutical Market by Sales Channels: Proportional Revenue Increases ($bn), 2015-2025
Figure 8.6 Fragmented Nature of the Chinese Pharmaceutical Distribution Market: Market Share by Revenue for the Leading Five Distributors (%), 2014
Figure 8.7 Chinese Hospital Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.8 Chinese Retail Pharmacy Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.9 Chinese Grassroot Clinics Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.10 Chinese Pharmaceuticals Sales Through Other Channels: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025
Figure 9.1 Top 50 Domestic Chinese Pharmaceutical Companies: Revenue ($bn), 2014
Figure 9.2 Distribution of Pharmaceutical Drugs Revenue by Top 5 and Top 10 Companies in Leading Markets: Market Share (%), 2014
Figure 9.3 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Share (%) of the Total Chinese Pharma Market, 2014
Figure 9.4 Chinese Pharmaceutical Market: Drivers and Restraints for MNCs' Growth, 2015-2025
Figure 11.1 The Rising Middle Class in China: Households With over $7,000 of Disposable Annual Income (millions), Annual Growth Rate, 2014-2030
Figure 11.2 The Ageing Population in China: Number of People Over 65 (millions), Proportion of the Total Population (%), 2014-2030
Figure 12.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2014, 2019, 2025
Figure 12.2 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), 2014, 2019, 2025
Figure 12.3 Summary of the Chinese Pharmaceutical Sales Channels: Market Size ($bn), 2014, 2019, 2025

【レポートのキーワード】

製薬、感染症、癌、循環器疾患、糖尿病、呼吸器疾患、自己免疫疾患、中枢神経障害、治療薬、医薬品、中国

★調査レポート[中国の製薬市場:動向、改革、機会、収益予測] ( Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 / VGAIN5091106) 販売に関する免責事項
[中国の製薬市場:動向、改革、機会、収益予測] ( Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 / VGAIN5091106) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆